일동제약

249420KOSPI

56.7 / 100

Reference Date: 2026-09-08

Financial Score18.0 / 40

News Sentiment18.7 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 1.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Il Dong Pharmaceutical is a company engaged in the manufacture and sale of pharmaceuticals, raw materials, and health supplements. Key products include Aronamin, Furumarin, and Laviert, with sales of 614,941 million won in the 9th fiscal year. Products are distributed domestically and internationally through channels such as wholesale, retail, and hospitals, with active R&D investments.

Number of Employees

1,104people

Average Salary

79.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

15.97Industry Average 15.003.0Point

Higher than industry avg (caution)

PBR

1.99Industry Average 1.201.0Point

1.7x industry avg (risky)

ROE

11.89Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

42.82Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20253.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼2.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲86.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -13.0% (improving, 3yr)

Detailed News Sentiment

27 totalPositive 17Neutral 4Negative 6Average Sentiment Score 74.6

Positive
P-CAB 신약 경쟁의 새로운 룰…'얼마나 다양한 환자에게' 초점
일동제약의 국산 신약들이 적응증 확대를 통해 시장 경쟁력을 강화하고 있어 긍정적인 전망을 제공합니다.
Positive
[애프터마켓 리뷰] K-바이오 재평가 기대 확산…일동제약 등 급등
일동제약 주가 급등, 바이오 시장 재평가 기대
Positive
관절염약이 탈모약으로? 애브비 ‘린버크’ 임상 결과에 국내 제네릭...
일동제약 관련 관절염 치료제의 임상 결과가 탈모 치료 효과로 확장되어 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (8%, downtrend)

Current 15,040Won52-week high 44,30052-week low 12,150

1-month return3.0Point

1m -1.83% (flat)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14